This page shows what was measured, who it was measured in, and what that does not settle.
What Mifepristone does in the body
From the FDA-approved label: Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses.
Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
Why people take it. Type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 320T6RNW1F · read 2026-08-29
Its recorded molecular formula is C29H35NO2, weighing 429.60.
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The recorded use, written for a reader without medical training. Not signed off.
No statement of the main limit is recorded.
The four opening statements run to 79 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Mood
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Body weight
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved1 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Mood
hamilton depression rating scale
Body weight
body weight
Blood sugar
insulin sensitivity index
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered symptom measure.
— Not recorded
Harms were not a registered measure for this goal.
△ Only a number moved
1 registered test measure.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Continued, ongoing pregnancy
✗ The study did not show it
Who was studied
NCT01410266
How many people
2400
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Abortion completion
✗ The study did not show it
Who was studied
NCT07174856
How many people
1900
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
successful menstrual regulation without the need for a surgical evacuation
✗ The study did not show it
Who was studied
NCT01798017
How many people
1738
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Continued, ongoing pregnancy
✗ The study did not show it
Who was studied
NCT01150422
How many people
1500
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Need for surgical completion for incomplete abortions or ongoing viable pregnancies at follow up visit Study day 15.
✗ The study did not show it
Who was studied
NCT00286208
How many people
1443
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Efficacy: Proportion of women who successfully complete abortion without surgical intervention to resolve viable pregnancy or incomplete abortion
✗ The study did not show it
Who was studied
NCT00997347
How many people
1400
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.4 registered measures of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.2 registered measures of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.4 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in C. elegans (roundworm), Drosophila (fruit fly), Mouse. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
hamilton depression rating scale
improvement in quality of life
Measured
Things only a test, a scale or a device shows.
body weight
blood pressure
insulin sensitivity index
hemoglobin a1c
Meaningful
Things that change how a life goes, not only a number.
progression free survival at 6 months
psa progression free survival
overall survival
progression free survival
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (30)
induction to delivery time
objective tumor response
overall response
duration of response
cortisol level
adverse events
complete abortion rate
procedure time
total procedure time
skin conductance response
initial cervical dilation at the time of surgical abortion
operative time
women who have undergone a successful abortion
cognition
homa ir
gestational sac expulsion by the 30 day telephone call
uterine asperation
rate of successful evacuation of the uterus
initial cervical dilation
rate of successful abortion by 24 hours
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of mifepristone in pediatric patients have not been established.”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
On older people, the label states: “Clinical studies with mifepristone did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger people.”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Mifepristone is contraindicated in pregnancy because the use of mifepristone results in pregnancy loss.”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Mifepristone is present in human milk, however, there are no data on the amount of mifepristone in human milk, the effects on the breastfed infant, or the effects on milk production during long term use of mifepristone (see Data) .”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
On people with reduced liver function, the label states: “In patients with mild to moderate hepatic impairment, the maximum dose should not exceed 600 mg per day.”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
On people with reduced kidney function, the label states: “The maximum dose should not exceed 600 mg per day in renally impaired patients. [See Clinical Pharmacology ( 12.3 )]”
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S5, S6.
No source is stored against this line.
What is in the pack
Sold as tablet, tablet, film coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Mifepristone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1406 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
abortion incomplete — 373 reaction mentions
haemorrhage — 357 reaction mentions
pregnancy — 125 reaction mentions
anaemia — 109 reaction mentions
pain — 97 reaction mentions
muscle spasms — 81 reaction mentions
vomiting — 73 reaction mentions
dizziness — 72 reaction mentions
pyrexia — 62 reaction mentions
vaginal haemorrhage — 57 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
16 products list this as an active ingredient in the United States drug directory. 16 of them contain it and nothing else.
FDA National Drug Code directory · 44132-005 · read 2026-08-29
They are sold as powder, tablet and tablet, film coated, taken oral.
FDA National Drug Code directory · 44132-005 · read 2026-08-29
The regulator's established pharmacologic class for it is progestational hormone receptor antagonists [moa] and progestin antagonist [epc].
FDA National Drug Code directory · 44132-005 · read 2026-08-29
5 published labels name it as an active ingredient. 5 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-29
Mifepristone is oral at 3 DOSAGE FORMS AND STRENGTHS Tablets: 300 mg Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side., recorded as fda label in effect 2025-09-25 in the United States.
US prescribing information · 63c068cd-9370-460f-829b-70e8c7ebe91e · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Mifepristone studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Mifepristone are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
5 documents were read for this substance.
RNAWiki source record
2 of them state the same halfLife, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
320T6RNW1F
RxNorm concept
1245262
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S5, S6.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
5 approved applications cover products containing this substance. The earliest was NDA020687, approved 20000928 to DANCO LABS LLC.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q2
What did Mifepristone's largest trial (884 people) and its longest (20 years) measure?
884 people in Mifepristone's largest registered study, 20 years in its longest registered window, measuring Mechanistic effects on biomarker relationships. ClinicalTrials.gov · 2026-09-01
46 phase2, 31 phase3, 27 phase4, 20 na, 20 phase1, 4 early phase1, 3 na or unstated; NCT03015701; 2012-11; no ageing endpoint recorded. Last human test completed 2025, NCT04254627.
Interpretation These counts include studies where Mifepristone was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
46
phase3
31
phase4
27
na
20
phase1
20
early phase1
4
2 more recorded rows
na or unstated
3
Last recorded human testNCT04254627
2025-09-30
recorded 2026-09-01 · last checked 2026-09-04
Q3
From C. elegans to human: where has Mifepristone shown lifespan?
safety (2), accrual/recruitment (12), funding/business (7), sponsor decision unspecified (1) and other (5): Mifepristone's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"DRC recommended stopping study as it had missed its primary endpoint"; 27 of 137 registered studies
Show the evidence
Trial
NCT00637494
terminated; "DRC recommended stopping study as it had missed its primary endpoint"
NCT00725270
terminated; "Lack of funding."
NCT00832871
terminated; "Low accrual; 4 patients enrolled between 2008-2015"
NCT00867360
terminated; "Insufficient recruitment."
NCT01138553
terminated; "Inadequate subject accrual"
NCT01212588
terminated; "Funding ended"
14 further recorded trials
NCT01224509
terminated; "Longer than expected recruitment period."
NCT01636063
terminated; "Poor subject enrollment"
NCT01925092
withdrawn; "Lack of enrollment"
NCT02099825
terminated; "COVID and staffing issues"
NCT02342002
terminated; "lack of funding"
NCT02620904
terminated; "unable to recruit. Projected completion was 2018 however, enrollment and recruitment were difficult. The study was terminated due to inability to enroll."
NCT02633761
terminated; "Lack of funding"
NCT02642939
terminated; "Lack of enrollment"
NCT02679092
withdrawn; "Funding changes."
NCT02704481
terminated; "Funding mechanism compromised"
NCT03052400
terminated; "End of Funding"
NCT03210324
terminated; "It is difficult to recruit enough participants"
NCT03212352
terminated; "Advised by DSMB based on interim-analysis, highly significant difference."
NCT03225547
terminated; "side effects (rash)"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Mifepristone used mifepristone 600 mg — over how long?
12 recorded entries; human; also "mifepristone 600 mg", "mifepristone 1200 mg", "mifepristone 200 mg"
Show the evidence
human
NCT00128479
mifepristone 600 mg
NCT00128479
mifepristone 1200 mg
NCT00986921
mifepristone 200 mg
NCT01294319
Mifepristone 400 MG
NCT01294319
Mifepristone 400 MG and Spironolactone 200 MG
NCT02179749
Mifepristone 1200 mg daily
6 more recorded rows
humanNCT03052400
Mifepristone 600 mg daily
humanNCT03065660
Mifepristone, Oral, 200 Mg
humanNCT03259542
Mifepristone 300 MG
humanNCT03714880
Mifepristone 200 MG
humanNCT03829696
Mifeprex® (Mifepristone 200 mg)
humanNCT06394999
Mifepristone 50 mg
recorded 2026-09-01 · last checked 2026-09-04
Q6
More Mifepristone was worse in human: at what point?
U-shaped in human: "Mifepristone administration resulted in a U-shaped response in the FST (with 1 mg/Kg, s.c., decreasing the immobility time) without significantly impacting the behavior in the EPM." Europe PMC · dose-response search · 2022-12-07
5 recorded sentences naming Mifepristone; U-shaped, hormetic, dose-response, dose response
Show the evidence
U-shapedPMID 36469636
"Mifepristone administration resulted in a U-shaped response in the FST (with 1 mg/Kg, s.c., decreasing the immobility time) without significantly impacting the behavior in the EPM."
hormeticPMID 23262305
"Also, since C. salmositica responds to both native and synthetic glucocorticoids and to the GR antagonist, RU486, and exhibits a biphasic (hormetic) response to the amount of cortisol in the medium, we propose that the glucocorticoid exerts its effects via an interaction with GR-like proteins in C. salmositica that are functionally similar to those present in vertebrate cells."
dose-responsePMID 35338548
"Mifepristone induced preterm birth, and an obvious dose-response was found."
dose response
PMID 30325501
"The effect of dose response and combination treatment with mifepristone and analogs of progesterone- or glucocorticoid-receptors were investigated on BRCA<sup>1-/2-</sup> MSC in vitro using a panel of markers for proliferation (ki67, BrdU, CDK2, p21<sup>CIP</sup> ), apoptosis (BAX, BCL2, CASPASE3), tumor suppression (TP53, PTEN) and cell survival (PI3KCA, MAPK3, mTOR)."
PMID 30325501
"The dose response with mifepristone treatment suggested an optimal effect with 10 μm mifepristone, exhibiting >90% viability and significantly reducing growth signaling markers (TP53 and MAPK3)."
recorded 2022-12-07 · last checked 2026-09-04
Q7
Which of adverse events, blood pressure and body weight did Mifepristone's trials measure?
adverse events, blood pressure and body weight lead 40 outcome terms across Mifepristone's trials. ClinicalTrials.gov · 2026-09-01
Interpretation objective tumor response, overall response, body weight, blood pressure, duration of response and cortisol level follow.
Show the evidence
hamilton depression rating scale
1
induction to delivery time
1
progression free survival at 6 months
1
objective tumor response
1
overall response
1
body weight
1
14 more recorded rows
blood pressure
1
duration of response
1
cortisol level
1
adverse events
1
insulin sensitivity index
1
complete abortion rate
1
procedure time
1
total procedure time
1
skin conductance response
1
initial cervical dilation at the time of surgical abortion
1
operative time
1
women who have undergone a successful abortion
1
cognition
1
homa ir
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Mifepristone's 7 ongoing trials reports first?
Progression-free Survival (PFS); Measure of women in labour or delivered within 2 days of intervention; latest 2028-06-05
Show the evidence
Trial
NCT02788981
"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer"; n 29; "Progression-free Survival (PFS)"; 2026-08
NCT05177510
"Mifepristone Outpatient Labour Induction"; n 400; "Measure of women in labour or delivered within 2 days of intervention"; 2027-05-31
NCT05341817
"The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy"; n 144; "Rate of complete abortion by Day 21-28"; 2025-11
NCT06099769
"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer"; n 201; "progression-free survival (PFS)"; 2027-10
NCT06394999
"Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive"; n 615; "Overall Pearl Index"; 2028-01-01
NCT06502158
"Mifepristone vs Misoprostol"; n 94; "Percentage of participants achieving Intended dilation"; 2027-06
1 further recorded trialNCT06733727
"Letrozole Versus Mifepristone and Misoprostol in Silent Miscarriage"; n 884; "Gestational sac expulsion"; 2028-06-05
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Mifepristone could settle lifespan?
NCT02788981 measures Progression-free Survival (PFS), reading out 2026-08.
2 open trials; n 29; "Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer"
Show the evidence
Trial
NCT02788981
"Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer"; n 29; "Progression-free Survival (PFS)"; 2026-08
NCT06099769
"A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer"; n 201; "progression-free survival (PFS)"; 2027-10
Q10
Which 46 trials of Mifepristone posted no result?
Posted no result
46 of 46 completed trials
Registrations
NCT00046553, NCT00945997, NCT00099645, NCT00130676, NCT00383032 and NCT00146523, and 40 more
Completion dates
oldest 2004-10; newest 2023-05-08
Show the evidence
Trial
NCT00046553
2004-10
NCT00945997
2005-03
NCT00099645
2005-08
NCT00130676
2006-06
NCT00383032
2006-06
NCT00146523
2006-07
14 further recorded trials
NCT00128505
2006-11
NCT00208156
2006-11
NCT00128479
2007-01
NCT00579475
2007-06
NCT00043654
2007-06-25
NCT00455442
2007-07
NCT00140478
2008-01
NCT00410345
2008-05
NCT00505739
2008-05
NCT00680394
2008-05
NCT00712595
2009-03
NCT00886873
2009-05
NCT00721201
2010-03
NCT00994734
2011-02
Q11
At the median, Mifepristone's trials enrolled 59 people — anything larger?
Median enrolment
59
Largest enrolment
884
Registered trials counted
136
Q12
What do 1406 spontaneous reports say about Mifepristone — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Mifepristone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1406 reaction mentions were counted: abortion incomplete 373; haemorrhage 357; pregnancy 125; anaemia 109. open-targets-adr · CHEMBL1276308 · 2026-06-24
Show the evidence
abortion incomplete
373
haemorrhage
357
pregnancy
125
anaemia
109
pain
97
muscle spasms
81
4 more recorded rows
vomiting
73
dizziness
72
pyrexia
62
vaginal haemorrhage
57
recorded 2026-06-24 · last checked 2026-09-04
Q13
Mifepristone and CYP3A4, BCRP and CYP1A2: shared by which compounds?
CYP3A4, BCRP and CYP1A2 appear in Mifepristone's recorded interaction sentences, 9 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP2A6pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP2B6pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP2C19pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP2C8pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP2D6pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
1 more recorded row
CYP2E1pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
CYP3A4
pharmacokinetics
Metabolism Cytochrome P450 3A4 (CYP3A4) has been shown to be involved in mifepristone metabolism in human liver microsomes.
pharmacokinetics
Drug-Drug Interactions In Vitro Assessment of Drug Interactions In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Mifepristone studied with fasting and exercise?
fasting and exercise are named in Mifepristone's label sentences: "Each subject was randomized at the beginning to receive a 25-mg tablet of the test or the reference mifepristone under fasting conditions during the first period, then received the alternate formulation during the second period following a 2-week washout period." openfda-label+europepmc · 2026-08-30
2 recorded statements; fasting, exercise
Show the evidence
fasting
Each subject was randomized at the beginning to receive a 25-mg tablet of the test or the reference mifepristone under fasting conditions during the first period, then received the alternate formulation during the second period following a 2-week washout period.
exercise
After reviewing the published and ongoing registered clinical trials for cognitive-behavioral therapy, exercise therapy, acupuncture, coenzyme Q10, mifepristone, and carnosine in GWI patients, we identified only four treatments (cognitive-behavioral therapy, exercise therapy, CoQ10, and mifepristone) that have progressed beyond a phase II trial.We conclude that progress in the scientific study of…
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Mifepristone and autophagy?
"GR inhibitor RU486 prevented light-induced up-regulation of RORα and the activation of autophagy." — where Mifepristone and autophagy appear together. Europe PMC · pathway abstract search · 2019-09-03
"GR inhibitor RU486 prevented light-induced up-regulation of RORα and the activation of autophagy."
IGF-1
PMID 31564832
"IGF-1 significantly promoted cell growth, while IGF-1 knockdown and mifepristone showed synergistic inhibition effects on cell growth."
PMID 31564832
"Our study for the first time demonstrated that IGF-1 signaling via ERK1/2 appears to be an important target of mifepristone in the treatment of uterine leiomyomas, which may provide a new approach to avoid leiomyoma re-growth after cessation of mifepristone."
AMPKPMID 28943275
"Mifepristone enhanced insulin-stimulated glucose uptake through a mechanism that involves a decrease in mitochondrial function and AMPK activation in skeletal muscle cells."
autophagyPMID 30390418
"This progesterone-induced increase in apoptosis was reversed by the inhibition of autophagy induction using either mifepristone (progesterone receptor modulator) or PTEN inhibitor."
mTORPMID 22154800
"Both the increase in LC3-II levels and activation of Akt and mTOR by neurosteroids were all mediated by PG receptors, as the effects were blocked by the addition of RU-486, a PG receptor antagonist."
AMPKPMID 24693963
"To determine whether any cross talk occurs among hypothalamic GC receptors (GRs), AMP-activated protein kinase (AMPK), and GCs in the regulation of appetite, we performed an intracerebroventricular injection of mifepristone (a GR inhibitor) and compound C (an AMPK inhibitor) on GC-treated male chicks."
autophagyPMID 26993765
"BAY 11-7085-induced cell death was significantly decreased with glucocorticoid inhibitor mifepristone and with inhibitors of autophagy."
AMPKPMID 22848740
"Induction of FOXO3 transcription by GR-binding steroids was reversed by concomitant treatment with the GR antagonist RU-486, but further enhanced by stimuli that activate the AMP-activated protein kinase (AMPK)."
recorded 2019-09-03 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.